Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03190837 · ClinicalTrials.gov registry record

A Long-term Follow-up Study of Gaucher Disease

A clinical trial of Gaucher Disease, sponsored by Duke University.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT03190837 is a study of Gaucher Disease that is actively recruiting participants, run by Duke University. The registered enrollment target is 200 participants, below the 1,043-participant average among 13 other Gaucher Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03190837, a study of Gaucher Disease, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The study aims are to: a) identify the long-term natural history of Gaucher disease, b) evaluate long-term treatment efficacy of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), and c) identify potential long-term complications of this disorder. These aims will be accomplished through long-term record review of individuals with all three types of Gaucher disease.

Conditions Studied

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2017-06-12
Est. Completion 2027-01

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT03190837

The ClinicalTrials.gov registry entry for NCT03190837 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,043-participant average among 13 other Gaucher Disease trials with a reported enrollment target (81% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03190837 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03190837 about?

NCT03190837 is a clinical study titled "A Long-term Follow-up Study of Gaucher Disease". The study aims are to: a) identify the long-term natural history of Gaucher disease, b) evaluate long-term treatment efficacy of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), and c) identify potential long-term complications of this disorder. These aims will be accomplished...

What is the current status of trial NCT03190837?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2017-06-12. Estimated completion is 2027-01.

What conditions does trial NCT03190837 study?

This clinical trial studies the following conditions: Gaucher Disease.

Who is sponsoring clinical trial NCT03190837?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03190837 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gaucher Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.